A Novel Telomerase Activator Suppresses Lung Damage in a Murine Model of Idiopathic Pulmonary Fibrosis

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Le Saux, Claude Jourdan ^a   Davy, Philip ^b   Brampton, Christopher ^b   Ahuja, Seema S ^a   Fauce, Steven ^c,e   Shivshankar, Pooja ^a   Nguyen, Hieu ^b   Ramaseshan, Mahesh ^c   Tressler, Robert ^c,d   Pirot, Zhu ^c   Harley, Calvin B ^c,f   Allsopp, Richard ^b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b UNIVERSITY OF HAWAII   (United States)

^c GERON CORPORATION   (United States)

^d Cellerant   (United States)

^e BECKMAN COULTER INC   (United States)

^f Telome Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; GRN 510; IMETELSTAT; RESPIRATORY TRACT AGENT; TELOMERASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL AGING; CELL SURVIVAL; COLLAGEN METABOLISM; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG MEGADOSE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ANALYSIS; EPITHELIUM CELL; EX VIVO STUDY; EXPERIMENTAL MODEL; FIBROSING ALVEOLITIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; LUNG FIBROBLAST; LUNG INJURY; MOUSE; NONHUMAN; PROTECTION; SMALL AIRWAY EPITHELIAL CELL; WILD TYPE;

ANIMALS; BLEOMYCIN; CELL AGING; COLLAGEN; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATORS; FIBROBLASTS; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INFLAMMATION; LUNG; MICE; PNEUMOCYTES; RESPIRATORY MUCOSA; SAPOGENINS; TELOMERASE;

EID: 84875031700     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058423     Document Type: Article

References (46)

1. Harley CB, (1991) Telomere loss: mitotic clock or genetic time bomb? Mutat Res 256: 271-282.
2. Buchkovich KJ, Greider CW, (1996) Telomerase regulation during entry into the cell cycle in normal human T cells. Mol Biol Cell 7: 1443-1454.
3. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, et al. (1994) Specific association of human telomerase activity with immortal cells and cancer. Science 266: 2011-2015.
4. Chiu CP, Dragowska W, Kim NW, Vaziri H, Yui J, et al. (1996) Differential expression of telomerase activity in hematopoietic progenitors from adult human bone marrow. Stem Cells 14: 239-248.
5. Hemann MT, Strong MA, Hao LY, Greider CW, (2001) The shortest telomere, not average telomere length, is critical for cell viability and chromosome stability. Cell 107: 67-77.
6. Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, et al. (1998) Extension of life-span by introduction of telomerase into normal human cells. Science 279: 349-352.
7. Effros RB, Allsopp R, Chiu CP, Hausner MA, Hirji K, et al. (1996) Shortened telomeres in the expanded CD28-CD8+ cell subset in HIV disease implicate replicative senescence in HIV pathogenesis. AIDS 10: F17-22.
8. Mitchell JR, Wood E, Collins K, (1999) A telomerase component is defective in the human disease dyskeratosis congenita. Nature 402: 551-555.
9. Vulliamy TJ, Marrone A, Knight SW, Walne A, Mason PJ, et al. (2006) Mutations in dyskeratosis congenita: their impact on telomere length and the diversity of clinical presentation. Blood 107: 2680-2685.
10. Yamaguchi H, Calado RT, Ly H, Kajigaya S, Baerlocher GM, et al. (2005) Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia. N Engl J Med 352: 1413-1424.
11. Armanios MY, Chen JJ, Cogan JD, Alder JK, Ingersoll RG, et al. (2007) Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med 356: 1317-1326.
12. Alder JK, Chen JJ, Lancaster L, Danoff S, Su SC, et al. (2008) Short telomeres are a risk factor for idiopathic pulmonary fibrosis. Proc Natl Acad Sci U S A 105: 13051-13056.
13. Diaz de Leon A, Cronkhite JT, Katzenstein AL, Godwin JD, Raghu G,et al. Telomere lengths, pulmonary fibrosis and telomerase (TERT) mutations. PLoS One 5: e10680.
14. Maher TM, Wells AU, Laurent GJ, (2007) Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms? Eur Respir J 30: 835-839.
15. Selman M, King TE, Pardo A, (2001) Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 134: 136-151.
16. Drakopanagiotakis F, Xifteri A, Polychronopoulos V, Bouros D, (2008) Apoptosis in lung injury and fibrosis. Eur Respir J 32: 1631-1638.
17. Wang Y, Kuan PJ, Xing C, Cronkhite JT, Torres F, et al. (2009) Genetic defects in surfactant protein A2 are associated with pulmonary fibrosis and lung cancer. Am J Hum Genet 84: 52-59.
18. Marshall RP, Puddicombe A, Cookson WO, Laurent GJ, (2000) Adult familial cryptogenic fibrosing alveolitis in the United Kingdom. Thorax 55: 143-146.
19. Mushiroda T, Wattanapokayakit S, Takahashi A, Nukiwa T, Kudoh S, et al. (2008) A genome-wide association study identifies an association of a common variant in TERT with susceptibility to idiopathic pulmonary fibrosis. J Med Genet 45: 654-656.
20. Tsakiri KD, Cronkhite JT, Kuan PJ, Xing C, Raghu G, et al. (2007) Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc Natl Acad Sci U S A 104: 7552-7557.
21. Fauce SR, Jamieson BD, Chin AC, Mitsuyasu RT, Parish ST, et al. (2008) Telomerase-based pharmacologic enhancement of antiviral function of human CD8+ T lymphocytes. J Immunol 181: 7400-7406.
22. Liu Y, Snow BE, Hande MP, Yeung D, Erdmann NJ, et al. (2000) The telomerase reverse transcriptase is limiting and necessary for telomerase function in vivo. Curr Biol 10: 1459-1462.
23. Dasari A, Bartholomew JN, Volonte D, Galbiati F, (2006) Oxidative stress induces premature senescence by stimulating caveolin-1 gene transcription through p38 mitogen-activated protein kinase/Sp1-mediated activation of two GC-rich promoter elements. Cancer Res 66: 10805-10814.
24. Volonte D, Galbiati F, (2009) Caveolin-1, cellular senescence and pulmonary emphysema. Aging (Albany NY) 1: 831-835.
25. Allsopp RC, Cheshier S, Weissman IL, (2001) Telomere shortening accompanies increased cell cycle activity during serial transplantation of hematopoietic stem cells. J Exp Med 193: 917-924.
26. Fust A, LeBellego F, Iozzo RV, Roughley PJ, Ludwig MS, (2005) Alterations in lung mechanics in decorin-deficient mice. Am J Physiol Lung Cell Mol Physiol 288: L159-166.
27. Mehrad B, Burdick MD, Strieter RM, (2009) Fibrocyte CXCR4 regulation as a therapeutic target in pulmonary fibrosis. Int J Biochem Cell Biol 41: 1708-1718.
28. Debacq-Chainiaux F, Erusalimsky JD, Campisi J, Toussaint O, (2009) Protocols to detect senescence-associated beta-galactosidase (SA-betagal) activity, a biomarker of senescent cells in culture and in vivo. Nat Protoc 4: 1798-1806.
29. Stellato C, Beck LA, Gorgone GA, Proud D, Schall TJ, et al. (1995) Expression of the chemokine RANTES by a human bronchial epithelial cell line. Modulation by cytokines and glucocorticoids. J Immunol 155: 410-418.
30. Nichols WW, Murphy DG, Cristofalo VJ, Toji LH, Greene AE, et al. (1977) Characterization of a new human diploid cell strain, IMR-90. Science 196: 60-63.
31. Roth A, Harley CB, Baerlocher GM, (2010) Imetelstat (GRN163L)-telomerase-based cancer therapy. Recent Results Cancer Res 184: 221-234.
32. Fridlender ZG, Cohen PY, Golan O, Arish N, Wallach-Dayan S, et al. (2007) Telomerase activity in bleomycin-induced epithelial cell apoptosis and lung fibrosis. Eur Respir J 30: 205-213.
33. Park JI, Venteicher AS, Hong JY, Choi J, Jun S, et al. (2009) Telomerase modulates Wnt signalling by association with target gene chromatin. Nature 460: 66-72.
34. Keane MP, Belperio JA, Moore TA, Moore BB, Arenberg DA, et al. (1999) Neutralization of the CXC chemokine, macrophage inflammatory protein-2, attenuates bleomycin-induced pulmonary fibrosis. J Immunol 162: 5511-5518.
35. Mallick S, (2008) Outcome of patients with idiopathic pulmonary fibrosis (IPF) ventilated in intensive care unit. Respir Med 102: 1355-1359.
36. Stack BH, Choo-Kang YF, Heard BE, (1972) The prognosis of cryptogenic fibrosing alveolitis. Thorax 27: 535-542.
37. Moeller A, Ask K, Warburton D, Gauldie J, Kolb M, (2008) The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol 40: 362-382.
38. Kottmann RM, Hogan CM, Phipps RP, Sime PJ, (2009) Determinants of initiation and progression of idiopathic pulmonary fibrosis. Respirology 14: 917-933.
39. Liu T, Chung MJ, Ullenbruch M, Yu H, Jin H, et al. (2007) Telomerase activity is required for bleomycin-induced pulmonary fibrosis in mice. J Clin Invest 117: 3800-3809.
40. Lee J, Reddy R, Barsky L, Scholes J, Chen H, et al. (2009) Lung alveolar integrity is compromised by telomere shortening in telomerase-null mice. Am J Physiol Lung Cell Mol Physiol 296: L57-70.
41. Liu T, Hu B, Chung MJ, Ullenbruch M, Jin H, et al. (2006) Telomerase regulation of myofibroblast differentiation. Am J Respir Cell Mol Biol 34: 625-633.
42. Liu T, Nozaki Y, Phan SH, (2002) Regulation of telomerase activity in rat lung fibroblasts. Am J Respir Cell Mol Biol 26: 534-540.
43. Mazzucchelli GD, Gabelica V, Smargiasso N, Fleron M, Ashimwe W, et al. (2008) Proteome alteration induced by hTERT transfection of human fibroblast cells. Proteome Sci 6: 12.
44. Shivshankar P, Boyd AR, Le Saux CJ, Yeh IT, Orihuela CJ, (2011) Cellular senescence increases expression of bacterial ligands in the lungs and is positively correlated with increased susceptibility to pneumococcal pneumonia. Aging Cell 10: 798-806.
45. Verma S, Slutsky AS, (2007) Idiopathic pulmonary fibrosis-new insights. N Engl J Med 356: 1370-1372.
46. Thannickal VJ, Loyd JE, (2008) Idiopathic pulmonary fibrosis: a disorder of lung regeneration? Am J Respir Crit Care Med 178: 663-665.